恒瑞医药：公司自主研发的1类创新药硫酸艾玛昔替尼片已在国内获批，用于成人重度斑秃患者

Core Viewpoint - Heng Rui Medicine (600276) emphasizes its commitment to technological innovation and international development strategies to ensure sustainable growth and better returns for shareholders [1] Group 1 - The company has received domestic approval for its self-developed innovative drug, Sulfate Emamectin Benzoate Tablets, aimed at treating adult patients with severe alopecia areata [1]